Advitech reports first quarter 2009 - Financial results and highlights



    TSX VENTURE EXCHANGE: AVI

    QUEBEC CITY, May 29 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Corporation") (TSX Venture Exchange: AVI) today announces the financial
results for the first quarter ended March 31, 2009.

    FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2009 AND CASH FLOWS

    
    - Revenues amounted to $186,379 for the first quarter ended March 31,
      2009, compared to $77,298 for the same quarter in 2008, an increase of
      $109,081 or 141%.

    - The net loss amounted to $355,847 for the first quarter ended March 31,
      2009, compared to $442,920 for the quarter ended March 31, 2008, a
      decrease of $87,073 or 19.7%.

    - As at March 31, 2009, the Corporation had a cash position of $104,502.
      Operating activities accounted for $251,547 in cash decrease during the
      first quarter of 2009, represented by a net loss adjusted for items not
      affecting cash of $304,267, and a decrease in working capital
      requirements of $52,720, mainly due to a decrease in the stocks. Cash
      used in investment activities amounted to $5,398 most of which was
      related to investments in intellectual property protection. Moreover,
      the Corporation generated $83,223 in cash from financing activities
      during the first quarter of 2009. An amount of $182,906 was drawn
      against the line of credit, while an amount of $70,490 of financing
      expenses was incurred to complete the private placement with AgeChem
      Venture Fund L.P. A total of $29,193 was used for repayments on the
      bank loan and on capital leases.

    - The private placement with AgeChem Venture Fund L.P. had no effect on
      cash during the first quarter of 2009 since the proceeds of this
      placement were held under escrow until April 17, 2009, at which date
      all conditions required for disbursement have been satisfied.

    "Following its recapitalization in April 2009, Advitech has begun to put
in place its strategic plan adopted at the end of 2008" commented Renaud
Beauchesne, Executive Chairman at Advitech. Mr. Beauchesne added, "We have
strengthened our bases and have organized the growth of the Corporation. In
addition to the forecasted organic growth of Advitech's activities, we will
put in the next coming months a particular emphasis on the Corporation's
development by searching for opportunities for business combination".

    FIRST QUARTER 2009 HIGHLIGHTS AND SUBSEQUENT EVENTS

    - In January 2009, execution of an agreement with Purity Life Health
      Products, a Sunopta division, for the distribution of Dermylex(R) in
      Canada.

    - Completion with AgeChem Venture Fund L.P., on March 12, 2009, of a
      $1,000,000 private placement of 50,000,000 units at a price of $0.02
      per unit. Each unit issued as part of the private placement consists of
      one common share in the share capital of Advitech and of one common
      share purchase warrant. Each warrant will entitle its holder to
      purchase one common share at a price of $0.05 per share for a period of
      one year following the date of issuance of the warrants, and,
      thereafter, at a price of $0.10 per share until the fifth anniversary
      of the date of issuance of the warrants. AgeChem Venture Fund L.P. now
      directly holds 25.51% of Advitech's outstanding common shares.

    - Conversion on April 17, 2009 of 98.4% of the issued and outstanding
      debentures of Advitech, together with accrued interest thereon, which
      represented an aggregate amount of $2,091,710, into 104,585,485 common
      shares at a deemed price of $0.02 per share. This conversion represents
      for the Corporation annual interest savings of about $240,000.
    

    ABOUT ADVITECH INC. www.advitech.com:

    Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Advitech produces Dermylex(R) for the treatment of
mild-to-moderate psoriasis.
    Advitech has initiated an innovative wound healing research program to
develop new applications for both its XP-828L and IM technological platforms.

    This press release contains forward-looking statements, which reflect the
Corporation's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual results
could differ materially from those projected herein. The TSX Venture Exchange
does not accept responsibility for the adequacy or accuracy of this release.
    %SEDAR: 00021006EF




For further information:

For further information: Renaud Beauchesne, MBA, Executive Chairman,
Advitech Inc., (418) 686-7498, ext. 228, info@advitech.com; Serge Comeau,
Investor's relations, Advitech Inc., (514) 862-4160, s.comeau@advitech.com

Organization Profile

ADVITECH INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890